An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumour burden in mice bearing human castration-resistant prostate cancer, according to data presented here at the AACR Annual...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2o2l9wJ
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Related Articles Modulation of the Tumor Microenvironment by Epstein-Barr virus Latent Membrane Protein-1 in Nasopharyngeal Carcinoma....
-
Publication date: Available online 10 March 2018 Source: Radiotherapy and Oncology Author(s): Igor Shuryak, Eric J. Hall, David J. Bre...
-
Abstract Maternal obesity is associated with large-for-gestational-age (LGA) neonates and programming of obesity-related cardiovascular d...
-
Communicating with patients at the end of life is regarded as a difficult task, and speaking openly about death is often avoided.1,2 Around ...
-
Vol.15 No.3 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1MwoM6F via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου